Specifically, RABL6A has been found to promote tumor cell proliferation and survival by activating oncogenic factors such as ERK [13,14], AKT [15], and MDM2 [16] while inactivating tumor suppressive PP2A [15], p53 [16,17], and p27-RB1 [17,18] to control tumor cell proliferation and survival. Here, AKT1 is linked to neoplasm.